{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:35:14Z","timestamp":1761896114179,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.bcmd.2015.06.010","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T02:25:51Z","timestamp":1435026351000},"page":"211-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Increased values of the circulating PDGF\u03b2 sustains the \u201cwithdrawal syndrome\u201d after tyrosine kinase inhibitor discontinuation in patients affected by chronic myeloid leukemia"],"prefix":"10.1016","volume":"55","author":[{"given":"Sara","family":"Galimberti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Fontanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Barsotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Barat\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2015.06.010_bb0005","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?","volume":"32","author":"Richter","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2015.06.010_bb0010","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcmd.2015.06.010_bb0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.bcmd.2015.06.010_bb0020","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12185-012-1141-7","article-title":"Response to imatinib mesylate in patients with hypereosinophilic syndrome","volume":"96","author":"Arefi","year":"2012","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bcmd.2015.06.010_bb0025","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/cncr.11416","article-title":"Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders","volume":"97","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2015.06.010_bb0030","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar2981","article-title":"Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes","volume":"12","author":"Rosengren","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bcmd.2015.06.010_bb0035","first-page":"321","article-title":"Characterization of platelet-derived growth factor beta-receptor expressing cells in the vasculature of human rheumatoid synovium","volume":"64","author":"Reuterdahl","year":"1991","journal-title":"Lab. Invest."},{"key":"10.1016\/j.bcmd.2015.06.010_bb0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1872213X113079990021","article-title":"Imatinib mesylate: an innovation in treatment of autoimmune diseases","volume":"7","author":"Azizi","year":"2013","journal-title":"Recent Pat. Inflamm. Allergy Drug Discov."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615001102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615001102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:31:22Z","timestamp":1761049882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979615001102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1079979615001102"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.06.010","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased values of the circulating PDGF\u03b2 sustains the \u201cwithdrawal syndrome\u201d after tyrosine kinase inhibitor discontinuation in patients affected by chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}